Investigation of the relationship between serum sclerostin and dickkopf-1 protein levels with bone turnover in children and adolescents with type-1 diabetes mellitus

dc.contributor.authorKurban, Sevil
dc.contributor.authorEklioglu, Beray Selver
dc.contributor.authorSelver, Muhammed Burak
dc.date.accessioned2024-02-23T14:29:51Z
dc.date.available2024-02-23T14:29:51Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractObjectives Diabetes mellitus (DM) is widely known to have a detrimental effect on bone health and is associated with increased fracture risk. Recently, the Wnt/beta-catenin signaling pathway and its inhibitors sclerostin and dickkopf-1 (Dkk-1) were found to be involved in the control of bone mass. The present study aimed to measure serum sclerostin and Dkk-1 protein levels in children and adolescents with type-1 DM and compare with other bone turnover markers and bone mineral density (BMD). Methods This study was performed on 40 children and adolescents with type-I DM and 40 healthy children and adolescents. Anthropometric measurements and pubertal examination were done. In addition to laboratory analysis, dickkopf-1, sclerostin, cross-linked N-telopeptides of type I collagen (NTx), bone alkaline phosphatase (bALP), and osteocalcin levels were studied. BMD of the participants was measured by calcaneus ultrasonography. Results Dickkopf-1 levels of the children and adolescents with type-1 DM were significantly higher, vitamin D, NTx, osteocalcin, and phosphorus levels were significantly lower than those of the controls (p<0.001). Fasting blood glucose, HbA1c, and insulin were significantly higher in the type 1 DM group (p<0.01). Conclusions Both bone remodeling and its compensatory mechanism bone loss are lower in children and adolescents with type-1 DM than in the controls. Also, higher levels of Dkk-1 play a role in decreased bone turnover in these patients. Since Dkk-1 and sclerostin seem to take a role in treating metabolic bone diseases in the future, we believe that our findings are significant in this respective.en_US
dc.description.sponsorshipNecmettin Erbakan Universityen_US
dc.description.sponsorshipStudy was supported by Necmettin Erbakan University scientific research projects coordination unit.en_US
dc.identifier.doi10.1515/jpem-2022-0001
dc.identifier.endpage679en_US
dc.identifier.issn0334-018X
dc.identifier.issn2191-0251
dc.identifier.issue5en_US
dc.identifier.pmid35411762en_US
dc.identifier.scopus2-s2.0-85129114261en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage673en_US
dc.identifier.urihttps://doi.org/10.1515/jpem-2022-0001
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14889
dc.identifier.volume35en_US
dc.identifier.wosWOS:000780885300001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWalter De Gruyter Gmbhen_US
dc.relation.ispartofJournal Of Pediatric Endocrinology & Metabolismen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBone Turnoveren_US
dc.subjectChildrenen_US
dc.subjectDickkopf-1 Proteinen_US
dc.subjectInsulin Dependent (Type 1)Diabetes Mellitusen_US
dc.subjectSclerostinen_US
dc.titleInvestigation of the relationship between serum sclerostin and dickkopf-1 protein levels with bone turnover in children and adolescents with type-1 diabetes mellitusen_US
dc.typeArticleen_US

Dosyalar